Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40

Immunology Letters

Volumn 105, Issue 1, 2006, Pages 38-47

  Hernández S , Mayra Xiomara ^a   Barçante, Thales Augusto ^a   Vilela, Luciano ^b   Tafuri, Wagner Luiz ^a   Afonso, Luís Carlos Crocco ^c   Vieira, Leda Quercia ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Biomm S/A   (Brazil)

^c FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

Adjuvant; IL 12; Leishmania; Leishmaniasis; Parasite; Protozoa; Vaccine

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; LEISHMANIA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOOT PAD; IMMUNITY; INFECTION SENSITIVITY; LEISHMANIA; LEISHMANIASIS; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; VACCINATION; WILD TYPE;

ANIMALS; FEMALE; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-4; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN SUBUNITS; PROTOZOAN VACCINES;

EID: 33646478984     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2005.12.002     Document Type: Article

References (51)

1. Neva F., Sacks D., and Leishmaniasis. Trop Geogr Med (1990) 296-308
2. Almeida R.P., Barral-Netto M., De Jesus A.M., De Freitas L.A., Carvalho E.M., and Barral A. Biological behavior of Leishmania amazonensis isolated from humans with cutaneous, mucosal, or visceral leishmaniasis in BALB/C mice. Am J Trop Med Hyg 54 2 (1996) 178-184
3. Sacks D., and Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2 11 (2002) 845-858
4. Afonso L.C., and Scott P. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect Immun 61 7 (1993) 2952-2959
5. Jones D.E., Buxbaum L.U., and Scott P. IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection. J Immunol 165 1 (2000) 364-372
6. Jones D.E., Ackermann M.R., Wille U., Hunter C.A., and Scott P. Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. Infect Immun 70 4 (2002) 2151-2158
7. Soong L., Xu J.C., Grewal I.S., Kima P., Sun J., Longley B.J., et al. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 4 3 (1996) 263-273
8. Oliveira M.A., Santiago H.C., Lisboa C.R., Ceravollo I.P., Trinchieri G., Gazzinelli R.T., et al. Leishmania sp: comparative study with Toxoplasma gondii and Trypanosoma cruzi in their ability to initialize IL-12 and IFN-gamma synthesis. Exp Parasitol 95 2 (2000) 96-105
9. Barral-Netto M., Von Sohsten R.L., Teixeira M., dos Santos W.L., Pompeu M.L., Moreira R.A., et al. In vivo protective effect of the lectin from Canavalia brasiliensis on BALB/c mice infected by Leishmania amazonensis. Acta Trop 60 4 (1996) 237-250
10. Soong L., Chang C.H., Sun J., Longley Jr. B.J., Ruddle N.H., Flavell R.A., et al. Role of CD4+ T cells in pathogenesis associated with Leishmania amazonensis infection. J Immunol 158 11 (1997) 5374-5383
11. Terabe M., Kuramochi T., Ito M., Hatabu T., Sanjoba C., Chang K.P., et al. CD4+ cells are indispensable for ulcer development in murine cutaneous leishmaniasis. Infect Immun 68 8 (2000) 4574-4577
12. Silveira F.T., Lainson R., Shaw J.J., De Souza A.A., Ishikawa E.A., and Braga R.R. Cutaneous leishmaniasis due to Leishmania (Leishmania) amazonensis in Amazonian Brazil, and the significance of a negative Montenegro skin-test in human infections. Trans Roy Soc Trop Med Hyg 85 6 (1991) 735-738
13. Pirmez C., Yamamura M., Uyemura K., Paes-Oliveira M., Conceicao-Silva F., and Modlin R.L. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 91 4 (1993) 1390-1395
14. Afonso L.C., Scharton T.M., Vieira L.Q., Wysocka M., Trinchieri G., and Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263 5144 (1994) 235-237
15. Antunes C.M., Mayrink W., Magalhaes P.A., Costa C.A., Melo M.N., Dias M., et al. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol 15 4 (1986) 572-580
16. Costa C.A., Afonso L.C.C., Toledo V.P.C.P., Tavares C.A.P., Genaro O., and Mayrink W. Evaluation of an industrialized non-living promastigote vaccine against cutaneous leishmaniasis. Parassitologia 34 (1992) 45-51
17. Mayrink W., Da Costa C.A., Magalhaes P.A., Melo M.N., Dias M., Lima A.O., et al. A field trial of a vaccine against American dermal leishmaniasis. Trans Roy Soc Trop Med Hyg 73 4 (1979) 385-387
18. Scott P., Pearce E., Natovitz P., and Sher A. Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract. J Immunol 139 9 (1987) 3118-3125
19. De Luca P.M., Mayrink W., Alves C.R., Coutinho S.G., Oliveira M.P., Bertho A.L., et al. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine 17 9/10 (1999) 1179-1185
20. Marzochi K.B., Marzochi M.A., Silva A.F., Grativol N., Duarte R., Confort E.M., et al. Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil. Mem Inst Oswaldo Cruz 93 2 (1998) 205-212
21. Mayrink W., Williams P., Da Costa C.A., Magalhaes P.A., Melo M.N., Dias M., et al. An experimental vaccine against American dermal leishmaniasis: experience in the State of Espirito Santo, Brazil. Ann Trop Med Parasitol 79 3 (1985) 259-269
22. Mendonca S.C., De Luca P.M., Mayrink W., Restom T.G., Conceicao-Silva F., Da Cruz A.M., et al. Characterization of human T lymphocyte-mediated immune responses induced by a vaccine against American tegumentary leishmaniasis. Am J Trop Med Hyg 53 2 (1995) 195-201
23. Courret N., Prina E., Mougneau E., Saraiva E.M., Sacks D.L., Glaichenhaus N., et al. Presentation of the Leishmania antigen LACK by infected macrophages is dependent upon the virulence of the phagocytosed parasites. Eur J Immunol 29 3 (1999) 762-773
24. Vieira L.Q., Goldschmidt M., Nashleanas M., Pfeffer K., Mak T., and Scott P. Mice lacking the TNF receptor p55 fail to resolve lesions caused by infection with Leishmania major, but control parasite replication. J Immunol 157 2 (1996) 827-835
25. Heinzel F.P., Rerko R.M., Ahmed F., and Pearlman E. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J Immunol 155 2 (1995) 730-739
26. Torrentera F.A., Glaichenhaus N., Laman J.D., and Carlier Y. T-cell responses to immunodominant LACK antigen do not play a critical role in determining susceptibility of BALB/c mice to Leishmania mexicana. Infect Immun 69 1 (2001) 617-621
27. Lu X.Z., Liu X.M., Guo Y.C., and Yang X.G. Assessment of the BALB/c mice as a suitable animal model for the investigation of food allergy. Wei Sheng Yan Jiu 34 2 (2005) 211-213
28. Zhao Y., van Hasselt C.A., Woo K.S., Wong Y.O., Liang C.Y., and Leung P.C. Establishment of a modified intranasally ovabumin induced animal model of allergic rhinitis. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 40 3 (2005) 176-180
29. Cardoso S.R., da Silva J.C., da Costa R.T., Mayrink W., Melo M.N., Michalick M.S., et al. Identification and purification of immunogenic proteins from nonliving promastigote polyvalent Leishmania vaccine (Leishvacin). Rev Soc Bras Med Trop 36 2 (2003) 193-199
30. Colmenares M., Kima P.E., Samoff E., Soong L., and Mahon-Pratt D. Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection. Infect Immun 71 6 (2003) 3172-3182
31. Kar S., Metz C., and Mahon-Pratt D. CD4+ T cells play a dominant role in protection against New World leishmaniasis induced by vaccination with the P-4 amastigote antigen. Infect Immun 73 6 (2005) 3823-3827
32. Gately M.K., Renzetti L.M., Magram J., Stern A.S., Adorini L., Gubler U., et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 16 (1998) 495-521
33. Hsieh C.S., Macatonia S.E., Tripp C.S., Wolf S.F., O'Garra A., and Murphy K.M. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260 5107 (1993) 547-549
34. Manetti R., Parronchi P., Giudizi M.G., Piccinni M.P., Maggi E., Trinchieri G., et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177 4 (1993) 1199-1204
35. Manetti R., Gerosa F., Giudizi M.G., Biagiotti R., Parronchi P., Piccinni M.P., et al. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 179 4 (1994) 1273-1283
36. Belosevic M., Finbloom D.S., Van Der Meide P.H., Slayter M.V., and Nacy C.A. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J Immunol 143 1 (1989) 266-274
37. Decken K., Kohler G., Palmer-Lehmann K., Wunderlin A., Mattner F., Magram J., et al. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect Immun 66 10 (1998) 4994-5000
38. Heinzel F.P., Schoenhaut D.S., Rerko R.M., Rosser L.E., and Gately M.K. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 177 5 (1993) 1505-1509
39. Scott P. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol 147 9 (1991) 3149-3155
40. Sypek J.P., Chung C.L., Mayor S.E., Subramanyam J.M., Goldman S.J., Sieburth D.S., et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 177 6 (1993) 1797-1802
41. Mattner F., Magram J., Ferrante J., Launois P., Di Padova K., Behin R., et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 26 7 (1996) 1553-1559
42. Park A.Y., Hondowicz B.D., and Scott P. IL-12 is required to maintain a Th1 response during Leishmania major infection. J Immunol 165 2 (2000) 896-902
43. Scott P., Artis D., Uzonna J., and Zaph C. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Immunol Rev 201 1 (2004) 318-338
44. Buxbaum L.U., Uzonna J.E., Goldschmidt M.H., and Scott P. Control of New World cutaneous leishmaniasis is IL-12 independent but STAT4 dependent. Eur J Immunol 32 11 (2002) 3206-3215
45. Qi H., Ji J., Wanasen N., and Soong L. Enhanced replication of Leishmania amazonensis amastigotes in gamma interferon-stimulated murine macrophages: implications for the pathogenesis of cutaneous leishmaniasis. Infect Immun 72 2 (2004) 988-995
46. Coelho E.A.F., Tavares C.A.P., Carvalho F.A.A., Chaves K.F., Teixeira K.N., Rodrigues R.C., et al. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun 71 7 (2003) 3988-3994
47. Kenney R.T., Sacks D.L., Sypek J.P., Vilela L., Gam A.A., and Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 163 8 (1999) 4481-4488
48. Belkaid Y., Von S.E., Mendez S., Lira R., Caler E., Bertholet S., et al. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168 8 (2002) 3992-4000
49. Chan M.M. T cell response in murine Leishmania mexicana amazonensis infection: production of interferon-gamma by CD8+ cells. Eur J Immunol 23 5 (1993) 1181-1184
50. Chang J., Cho J.H., Lee S.W., Choi S.Y., Ha S.J., and Sung Y.C. IL-12 priming during in vitro antigenic stimulation changes properties of CD8 T cells and increases generation of effector and memory cells. J Immunol 172 5 (2004) 2818-2826
51. Jankovic D., Kullberg M.C., Hieny S., Caspar P., Collazo C.M., and Sher A. In the absence of IL-12, CD4(+) T cell responses to intracellular pathogens fail to default to a Th2 pattern and are host protective in an IL-10(-/-) setting. Immunity 16 3 (2002) 429-439